clinical trial · NCT07014826
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Chengdu Suncadia Medicine Co., Ltd.·phase3·active not recruiting·n = 389
Primary IgA NephropathyHRS-5965Placebo
brief summary
This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.
started
Jun 4, 2025
primary completion
Oct 1, 2027
completion
Dec 1, 2028
last updated
Nov 18, 2026
official title
Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of HRS-5965 Capsule in Primary IgA Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol